FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to a new humanized antibody; it can be used in medicine. The invention discloses an antibody capable of binding to a human alpha-enolase (ENO1) protein, which can be used in the medical practice in the therapy of a number of tumor diseases, cells of which express ENO1 protein on the surface in the form of a plasminogen receptor.
EFFECT: obtaining antibodies for the antitumor therapy.
11 cl, 13 dwg, 2 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTIBODIES TARGETING GALACTAN-BASED O-ANTIGEN FROM K.PNEUMONIAE | 2015 |
|
RU2759950C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2793783C1 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| HUMANISED ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (FAB) AGAINST FIRST AND/OR SECOND TYPE SHIGA LIKE TOXINS (EMBODIMENTS), COMPOSITION FOR TREATING ENTEROHAEMORRHAGIC ESCHERICHIA COLI TOXIC CONDITIONS, CONTAINING SAID ANTIBODIES AND/OR FAB | 2019 |
|
RU2732155C1 |
